​The Era of "Luck" is Over. Welcome to the Era of Engineering. 🧬 + 🤖

​For decades, rare disease innovation was stifled by the same math problem: Data Scarcity. Too few patients, too little natural history data, and markets deemed "too small" for traditional R&D.

​AI has finally inverted that equation.

​Join us during JPM Week for a high-signal evening dedicated to the Rare Disease Singularity. We are gathering the ecosystem—Tech, Bio, Policy, and Advocacy—to discuss how the convergence of Generative AI and Precision Medicine is transforming the entire stack.

​Why This Moment is Unique: We are moving beyond pilot programs to systemic transformation.

• ​Diagnostics (The End of the Odyssey): How V2P (Variant-to-Phenotype) models and AI-driven chart reviews are identifying "needles in the haystack" in minutes, not years—finding the patients that others miss.

• ​Therapeutics (The "N-of-1" Era): How Generative Biology and Synthetic Control Arms are allowing us to design de novo treatments and run statistically significant trials for ultra-rare populations, de-risking the path to approval.

• ​Care Management (The Patient Agent): Moving from reactive crisis management to predictive care, where AI agents act as 24/7 co-pilots for families, structuring Real-World Evidence (RWE) from the living room.

​Who is in the Room? This is a curated reception for the builders:

• ​Founders building the "Bio-Foundation Models" and agents powering precision medicine.

• ​Pharma leaders integrating AI into their R&D pipelines.

• ​The regulators and advocates rewriting the rules for data sovereignty and reimbursement.

• ​The patient leaders who control the most valuable asset in the industry: the registry.

​Agenda

• ​6:00 PM: Doors Open & "Convergence" Cocktails

  • ​Premium open bar and heavy hors d'oeuvres.

• ​7:00 PM: Lightning Talk: "Beyond the Diagnosis"

• ​7:15 PM: Ecosystem Networking

  • ​Facilitated introductions between those building the tech and those needing the cures.

• ​9:00 PM: Event Concludes